Navigation Links
Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
Date:10/5/2011

SAN DIEGO, Oct. 5, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Aethlon Hemopurifier® and HER2osome™ cancer therapy will be the subject of a presentation at the Exosomes and Microvesicles 2011 conference on October 17th.  The event is being held at the Wyndham Lake Buena Vista Resort located in Walt Disney World, Florida.  Dr. Annette Marleau, Director of Tumor Immunology at Aethlon Medical will give the presentation.  Both the Aethlon Hemopurifier® and HER2osome™ represent novel exosome-targeted strategies to improve cancer treatment outcomes.  Exosomes released by cancers have recently emerged to become therapeutic targets in cancer care, as they are implicated in cancer survival, growth, and metastasis.  Researchers have also identified that cancer-released exosomes assist tumors in evading the response of the immune system.  

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

About HER2osome™HER2osome™ provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer, which is characterized by aggressive growth and poor prognosis resulting from the over-expression of HER2 protein.  HER2osome™ is a novel medical device, whose goal is to inhibit HER2+ breast cancer progression by reducing the circulatory presence of HER2 protein and tumor-secreted exosomes that contribute to the development and progression of breast cancer.  Research publications indicate that breast cancer exosomes suppress the immune response, stimulate angiogenesis, contribute to the spread of metastasis, and inhibit the therapeutic benefit of Herceptin® (trastuzumab), a leading monoclonal antibody treatment against the HER2+ breast cancer.  As an adjunct therapeutic candidate, HER2osome™ offers to fill an unmet medical need and enhance the benefit of Herceptin® and standard of care chemotherapies without adding drug toxicity or interaction risks.  

About the Aethlon Hemopurifier®The Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens, including the human immunodeficiency virus (HIV), hepatitis C virus (HCV) and numerous bioterror and pandemic threats. Human studies have demonstrated the Hemopurifier® to be safe and provide average viral load reductions of greater than 50% during four-hour treatment periods in both HCV and HIV infected individuals without the administration of antiviral drugs.  The device is currently the subject of a human clinical study in India to evaluate its ability to accelerate viral load depletion when utilized in combination with HCV standard of care drug therapy.  An investigational device exemption (IDE) to initiate clinical studies in the United States is pending with The Food and Drug Administration (FDA).

In vitro studies have also documented that the Hemopurifier® captures exosomes underlying cancer, including colorectal, lymphoma, melanoma, ovarian, and breast cancer. Aethlon recently expanded its exosome research programs through a collaborative agreement with the Sarcoma Oncology Center (SOC), based in Santa Monica, California. The SOC collaboration is studying the ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.  The study will evaluate 25 patients, five patients with metastatic cancer of the following types; non-small cell lung cancer, prostate cancer, melanoma, head and neck cancer, and sarcoma.  

To support the advancement of its therapeutic candidates, Aethlon has developed a diagnostic assay known as ELLSA™ that is able to identify and quantify the presence of exosomes in blood and other fluids.  Aethlon plans to license or sell this technology to an organization already established in the research diagnostics field.

The Aethlon Hemopurifier® and HER2osome™ were both developed from the Aethlon ADAPT™ system, an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components.  Therapies that evolve from the Aethlon ADAPT™ system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size.  In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies.  Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT™ therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will market the ADAPT™ system to government agencies and organizations representing the pharmaceutical, biotechnology and medical device industry. On September 30, 2011, Aethlon was awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device from the ADAPT™ system that would reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.  

About Aethlon MedicalThe Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the ability to achieve the goals set out in the DARPA contract, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier® to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture exosomes and the impact it may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.Contacts:James A. JoyceChairman and CEO858.459.7800 x301jj@aethlonmedical.comJody CainSenior Vice President, Lippert/Heilshorn & Associates310.691.7100jcain@lhai.comJim FrakesChief Financial Officer858.459.7800 x300jfrakes@aethlonmedical.comJohn P. SalvadorDirector, Communications & Investor Relations858.459.7800 x307jps@aethlonmedical.com
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
2. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
3. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
4. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
5. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
8. Aethlon Medical Reestablishes Biodefense Programs
9. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
10. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
11. Aethlon Medical Names Rod Kenley President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... New York , May 26, 2016 ... Market Research "Medical Waste Management Market - U.S. Industry Analysis, ... medical waste management market in the U.S. was valued at ... at a CAGR of 3.4% from 2015 to 2023 to ... provides exhaustive analysis of current and emerging needle free drug ...
(Date:5/26/2016)... , May 26, 2016 A ... growth is the emergence of new treatments. Cardax, a ... for osteoarthritis treatment. The therapy is expected to fulfil ... Research UK is conducting studies to develop new treatments ... where the genes involved in osteoarthritis are being investigated, ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its ... manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more ... trusted by government agencies, including NASA. , In 2012, NASA strategically set up ...
(Date:5/26/2016)... ... ... An April Gallup survey found rising health care costs to be the ... Senior Living (SHSL) may not share those same worries thanks to a new ... year, while holding the line on increasing their contributions, including premiums, deductibles and the ...
(Date:5/26/2016)... ... 26, 2016 , ... Leadership of Life Science Logistics (LSL), ... has earned its ISO 13485 certification, indicating the company’s quality control system for ... policies associated with ISO quality standard 13485. , BSI Group America, Inc., ...
(Date:5/26/2016)... ... ... North Cypress Medical Center hosted its 9th Annual Spring Classic ... help of community partners, the event organizers raised $45,000 for the Lone Survivor ... and their families through health, wellness, and therapeutic support. , A special military ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The MIAMI Institute ... featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician ... Medicine, and a member of the Institute for Functional Medicine. , He also heads ...
Breaking Medicine News(10 mins):